Contrastingly, a decrease in the expression of 2B4 on CD56+ NK cells was observed in the high-risk (72.16%) and standard risk/low-risk (60.2%) ALL subjects at diagnosis (1BD) as compared to healthy (77.04%) subjects (Figure 3A). The gene discussed is NCAM1; the disease is acute lymphoblastic leukemia.